Increased expression of dopamine receptors on lymphocytes in Parkinson's disease
Identifieur interne : 002075 ( Main/Corpus ); précédent : 002074; suivant : 002076Increased expression of dopamine receptors on lymphocytes in Parkinson's disease
Auteurs : Piero Barbanti ; Giovanni Fabbrini ; Alberto Ricci ; Rosanna Cerbo ; Elena Bronzetti ; Brunella Caronti ; Caterina Calderaro ; Laura Felici ; Fabrizio Stocchi ; Giuseppe Meco ; Francesco Amenta ; Gian Luigi LenziSource :
- Movement Disorders [ 0885-3185 ] ; 1999-09.
English descriptors
- KwdEn :
Abstract
Dopamine D1‐like and D2‐like receptors on peripheral blood lymphocytes (PBL) were assayed in 50 de novo patients with idiopathic Parkinson's disease (PD), in 36 neurologic control subjects (multiple‐system atrophy, n = 16; essential tremor, n = 10; other neurodegenerative diseases, n = 10), and in 26 healthy control subjects by radioligand binding assay techniques using [3H]SCH 23390 and [3H]7OH‐DPAT as ligands. Patients with PD revealed a higher density (Bmax) of dopamine D1‐like (p <0.001) and D2‐like (p <0.00001) receptors on PBL than either neurologic or healthy control subjects, whereas no differences in Bmax were observed among patients affected by other neurologic diseases and healthy control subjects. The affinity (Kd) of both radioligands was similar in the groups investigated. The pharmacologic profile of [3H]SCH 23390 and [3H]7OH‐DPAT binding was consistent with the labeling of dopamine D5 and D3 receptor subtypes, respectively. Twenty‐five of the 50 patients with PD were retested after 3 months of therapy with levodopa or bromocriptine. Both treatments reduced the density of D1‐like (p <0.001) and D2‐like (p <0.001) receptors on PBL to values comparable to those of control subjects. The increased density of D1‐like and D2‐like receptors on PBL in de novo PD patients may represent an upregulation mechanism resulting from the diffuse impairment of the dopaminergic system in PD.
Url:
DOI: 10.1002/1531-8257(199909)14:5<764::AID-MDS1008>3.0.CO;2-W
Links to Exploration step
ISTEX:96D855F1FBF0045844CED703B6EAF55077826366Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Increased expression of dopamine receptors on lymphocytes in Parkinson's disease</title><author><name sortKey="Barbanti, Piero" sort="Barbanti, Piero" uniqKey="Barbanti P" first="Piero" last="Barbanti">Piero Barbanti</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Fabbrini, Giovanni" sort="Fabbrini, Giovanni" uniqKey="Fabbrini G" first="Giovanni" last="Fabbrini">Giovanni Fabbrini</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Ricci, Alberto" sort="Ricci, Alberto" uniqKey="Ricci A" first="Alberto" last="Ricci">Alberto Ricci</name><affiliation><mods:affiliation>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Cerbo, Rosanna" sort="Cerbo, Rosanna" uniqKey="Cerbo R" first="Rosanna" last="Cerbo">Rosanna Cerbo</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Bronzetti, Elena" sort="Bronzetti, Elena" uniqKey="Bronzetti E" first="Elena" last="Bronzetti">Elena Bronzetti</name><affiliation><mods:affiliation>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Caronti, Brunella" sort="Caronti, Brunella" uniqKey="Caronti B" first="Brunella" last="Caronti">Brunella Caronti</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Calderaro, Caterina" sort="Calderaro, Caterina" uniqKey="Calderaro C" first="Caterina" last="Calderaro">Caterina Calderaro</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Felici, Laura" sort="Felici, Laura" uniqKey="Felici L" first="Laura" last="Felici">Laura Felici</name><affiliation><mods:affiliation>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation><mods:affiliation>I.R.C.C.S. Neuromed, Pozzilli and the Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, Italy</mods:affiliation></affiliation></author><author><name sortKey="Meco, Giuseppe" sort="Meco, Giuseppe" uniqKey="Meco G" first="Giuseppe" last="Meco">Giuseppe Meco</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Amenta, Francesco" sort="Amenta, Francesco" uniqKey="Amenta F" first="Francesco" last="Amenta">Francesco Amenta</name><affiliation><mods:affiliation>Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, Italy</mods:affiliation></affiliation></author><author><name sortKey="Lenzi, Gian Luigi" sort="Lenzi, Gian Luigi" uniqKey="Lenzi G" first="Gian Luigi" last="Lenzi">Gian Luigi Lenzi</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:96D855F1FBF0045844CED703B6EAF55077826366</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199909)14:5<764::AID-MDS1008>3.0.CO;2-W</idno><idno type="url">https://api.istex.fr/document/96D855F1FBF0045844CED703B6EAF55077826366/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002075</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Increased expression of dopamine receptors on lymphocytes in Parkinson's disease</title><author><name sortKey="Barbanti, Piero" sort="Barbanti, Piero" uniqKey="Barbanti P" first="Piero" last="Barbanti">Piero Barbanti</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Fabbrini, Giovanni" sort="Fabbrini, Giovanni" uniqKey="Fabbrini G" first="Giovanni" last="Fabbrini">Giovanni Fabbrini</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Ricci, Alberto" sort="Ricci, Alberto" uniqKey="Ricci A" first="Alberto" last="Ricci">Alberto Ricci</name><affiliation><mods:affiliation>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Cerbo, Rosanna" sort="Cerbo, Rosanna" uniqKey="Cerbo R" first="Rosanna" last="Cerbo">Rosanna Cerbo</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Bronzetti, Elena" sort="Bronzetti, Elena" uniqKey="Bronzetti E" first="Elena" last="Bronzetti">Elena Bronzetti</name><affiliation><mods:affiliation>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Caronti, Brunella" sort="Caronti, Brunella" uniqKey="Caronti B" first="Brunella" last="Caronti">Brunella Caronti</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Calderaro, Caterina" sort="Calderaro, Caterina" uniqKey="Calderaro C" first="Caterina" last="Calderaro">Caterina Calderaro</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Felici, Laura" sort="Felici, Laura" uniqKey="Felici L" first="Laura" last="Felici">Laura Felici</name><affiliation><mods:affiliation>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Stocchi, Fabrizio" sort="Stocchi, Fabrizio" uniqKey="Stocchi F" first="Fabrizio" last="Stocchi">Fabrizio Stocchi</name><affiliation><mods:affiliation>I.R.C.C.S. Neuromed, Pozzilli and the Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, Italy</mods:affiliation></affiliation></author><author><name sortKey="Meco, Giuseppe" sort="Meco, Giuseppe" uniqKey="Meco G" first="Giuseppe" last="Meco">Giuseppe Meco</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author><author><name sortKey="Amenta, Francesco" sort="Amenta, Francesco" uniqKey="Amenta F" first="Francesco" last="Amenta">Francesco Amenta</name><affiliation><mods:affiliation>Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, Italy</mods:affiliation></affiliation></author><author><name sortKey="Lenzi, Gian Luigi" sort="Lenzi, Gian Luigi" uniqKey="Lenzi G" first="Gian Luigi" last="Lenzi">Gian Luigi Lenzi</name><affiliation><mods:affiliation>Department of Neurosciences, University “La Sapienza,” Rome</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-09">1999-09</date><biblScope unit="volume">14</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="764">764</biblScope><biblScope unit="page" to="771">771</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">96D855F1FBF0045844CED703B6EAF55077826366</idno><idno type="DOI">10.1002/1531-8257(199909)14:5<764::AID-MDS1008>3.0.CO;2-W</idno><idno type="ArticleID">MDS1008</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine receptor</term><term>Lymphocyte</term><term>Parkinson's disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine D1‐like and D2‐like receptors on peripheral blood lymphocytes (PBL) were assayed in 50 de novo patients with idiopathic Parkinson's disease (PD), in 36 neurologic control subjects (multiple‐system atrophy, n = 16; essential tremor, n = 10; other neurodegenerative diseases, n = 10), and in 26 healthy control subjects by radioligand binding assay techniques using [3H]SCH 23390 and [3H]7OH‐DPAT as ligands. Patients with PD revealed a higher density (Bmax) of dopamine D1‐like (p <0.001) and D2‐like (p <0.00001) receptors on PBL than either neurologic or healthy control subjects, whereas no differences in Bmax were observed among patients affected by other neurologic diseases and healthy control subjects. The affinity (Kd) of both radioligands was similar in the groups investigated. The pharmacologic profile of [3H]SCH 23390 and [3H]7OH‐DPAT binding was consistent with the labeling of dopamine D5 and D3 receptor subtypes, respectively. Twenty‐five of the 50 patients with PD were retested after 3 months of therapy with levodopa or bromocriptine. Both treatments reduced the density of D1‐like (p <0.001) and D2‐like (p <0.001) receptors on PBL to values comparable to those of control subjects. The increased density of D1‐like and D2‐like receptors on PBL in de novo PD patients may represent an upregulation mechanism resulting from the diffuse impairment of the dopaminergic system in PD.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Piero Barbanti MD, PhD</name><affiliations><json:string>Department of Neurosciences, University “La Sapienza,” Rome</json:string></affiliations></json:item><json:item><name>Giovanni Fabbrini MD</name><affiliations><json:string>Department of Neurosciences, University “La Sapienza,” Rome</json:string></affiliations></json:item><json:item><name>Alberto Ricci MD</name><affiliations><json:string>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</json:string></affiliations></json:item><json:item><name>Rosanna Cerbo MD</name><affiliations><json:string>Department of Neurosciences, University “La Sapienza,” Rome</json:string></affiliations></json:item><json:item><name>Elena Bronzetti PhD</name><affiliations><json:string>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</json:string></affiliations></json:item><json:item><name>Brunella Caronti PhD</name><affiliations><json:string>Department of Neurosciences, University “La Sapienza,” Rome</json:string></affiliations></json:item><json:item><name>Caterina Calderaro PhD</name><affiliations><json:string>Department of Neurosciences, University “La Sapienza,” Rome</json:string></affiliations></json:item><json:item><name>Laura Felici PhD</name><affiliations><json:string>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</json:string></affiliations></json:item><json:item><name>Fabrizio Stocchi MD, PhD</name><affiliations><json:string>I.R.C.C.S. Neuromed, Pozzilli and the Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, Italy</json:string></affiliations></json:item><json:item><name>Giuseppe Meco MD</name><affiliations><json:string>Department of Neurosciences, University “La Sapienza,” Rome</json:string></affiliations></json:item><json:item><name>Francesco Amenta MD</name><affiliations><json:string>Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, Italy</json:string></affiliations></json:item><json:item><name>Gian Luigi Lenzi MD</name><affiliations><json:string>Department of Neurosciences, University “La Sapienza,” Rome</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Dopamine receptor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Lymphocyte</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item></subject><articleId><json:string>MDS1008</json:string></articleId><language><json:string>eng</json:string></language><abstract>Dopamine D1‐like and D2‐like receptors on peripheral blood lymphocytes (PBL) were assayed in 50 de novo patients with idiopathic Parkinson's disease (PD), in 36 neurologic control subjects (multiple‐system atrophy, n = 16; essential tremor, n = 10; other neurodegenerative diseases, n = 10), and in 26 healthy control subjects by radioligand binding assay techniques using [3H]SCH 23390 and [3H]7OH‐DPAT as ligands. Patients with PD revealed a higher density (Bmax) of dopamine D1‐like (p >0.001) and D2‐like (p >0.00001) receptors on PBL than either neurologic or healthy control subjects, whereas no differences in Bmax were observed among patients affected by other neurologic diseases and healthy control subjects. The affinity (Kd) of both radioligands was similar in the groups investigated. The pharmacologic profile of [3H]SCH 23390 and [3H]7OH‐DPAT binding was consistent with the labeling of dopamine D5 and D3 receptor subtypes, respectively. Twenty‐five of the 50 patients with PD were retested after 3 months of therapy with levodopa or bromocriptine. Both treatments reduced the density of D1‐like (p >0.001) and D2‐like (p >0.001) receptors on PBL to values comparable to those of control subjects. The increased density of D1‐like and D2‐like receptors on PBL in de novo PD patients may represent an upregulation mechanism resulting from the diffuse impairment of the dopaminergic system in PD.</abstract><qualityIndicators><score>7.011</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1410</abstractCharCount><pdfWordCount>4455</pdfWordCount><pdfCharCount>28704</pdfCharCount><pdfPageCount>8</pdfPageCount><abstractWordCount>213</abstractWordCount></qualityIndicators><title>Increased expression of dopamine receptors on lymphocytes in Parkinson's disease</title><genre><json:string>article</json:string></genre><host><volume>14</volume><publisherId><json:string>MDS</json:string></publisherId><pages><total>8</total><last>771</last><first>764</first></pages><issn><json:string>0885-3185</json:string></issn><issue>5</issue><subject><json:item><value>Article</value></json:item></subject><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>1999</publicationDate><copyrightDate>1999</copyrightDate><doi><json:string>10.1002/1531-8257(199909)14:5>764::AID-MDS1008>3.0.CO;2-W</json:string></doi><id>96D855F1FBF0045844CED703B6EAF55077826366</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/96D855F1FBF0045844CED703B6EAF55077826366/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/96D855F1FBF0045844CED703B6EAF55077826366/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/96D855F1FBF0045844CED703B6EAF55077826366/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Increased expression of dopamine receptors on lymphocytes in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><availability><p>WILEY</p></availability><date>1999</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Increased expression of dopamine receptors on lymphocytes in Parkinson's disease</title><author><persName><forename type="first">Piero</forename><surname>Barbanti</surname></persName><roleName type="degree">MD, PhD</roleName><note type="correspondence"><p>Correspondence: Department of Neurosciences, University “La Sapienza,” Viale dell'Università, 30‐00185‐Rome, Italy</p></note><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation></author><author><persName><forename type="first">Giovanni</forename><surname>Fabbrini</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation></author><author><persName><forename type="first">Alberto</forename><surname>Ricci</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</affiliation></author><author><persName><forename type="first">Rosanna</forename><surname>Cerbo</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation></author><author><persName><forename type="first">Elena</forename><surname>Bronzetti</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</affiliation></author><author><persName><forename type="first">Brunella</forename><surname>Caronti</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation></author><author><persName><forename type="first">Caterina</forename><surname>Calderaro</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation></author><author><persName><forename type="first">Laura</forename><surname>Felici</surname></persName><roleName type="degree">PhD</roleName><affiliation>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</affiliation></author><author><persName><forename type="first">Fabrizio</forename><surname>Stocchi</surname></persName><roleName type="degree">MD, PhD</roleName><affiliation>I.R.C.C.S. Neuromed, Pozzilli and the Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, Italy</affiliation></author><author><persName><forename type="first">Giuseppe</forename><surname>Meco</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation></author><author><persName><forename type="first">Francesco</forename><surname>Amenta</surname></persName><roleName type="degree">MD</roleName><affiliation>Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, Italy</affiliation></author><author><persName><forename type="first">Gian Luigi</forename><surname>Lenzi</surname></persName><roleName type="degree">MD</roleName><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-09"></date><biblScope unit="volume">14</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="764">764</biblScope><biblScope unit="page" to="771">771</biblScope></imprint></monogr><idno type="istex">96D855F1FBF0045844CED703B6EAF55077826366</idno><idno type="DOI">10.1002/1531-8257(199909)14:5<764::AID-MDS1008>3.0.CO;2-W</idno><idno type="ArticleID">MDS1008</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1999</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Dopamine D1‐like and D2‐like receptors on peripheral blood lymphocytes (PBL) were assayed in 50 de novo patients with idiopathic Parkinson's disease (PD), in 36 neurologic control subjects (multiple‐system atrophy, n = 16; essential tremor, n = 10; other neurodegenerative diseases, n = 10), and in 26 healthy control subjects by radioligand binding assay techniques using [3H]SCH 23390 and [3H]7OH‐DPAT as ligands. Patients with PD revealed a higher density (Bmax) of dopamine D1‐like (p <0.001) and D2‐like (p <0.00001) receptors on PBL than either neurologic or healthy control subjects, whereas no differences in Bmax were observed among patients affected by other neurologic diseases and healthy control subjects. The affinity (Kd) of both radioligands was similar in the groups investigated. The pharmacologic profile of [3H]SCH 23390 and [3H]7OH‐DPAT binding was consistent with the labeling of dopamine D5 and D3 receptor subtypes, respectively. Twenty‐five of the 50 patients with PD were retested after 3 months of therapy with levodopa or bromocriptine. Both treatments reduced the density of D1‐like (p <0.001) and D2‐like (p <0.001) receptors on PBL to values comparable to those of control subjects. The increased density of D1‐like and D2‐like receptors on PBL in de novo PD patients may represent an upregulation mechanism resulting from the diffuse impairment of the dopaminergic system in PD.</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Dopamine receptor</term></item><item><term>Lymphocyte</term></item><item><term>Parkinson's disease</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1998-05-10">Received</change><change when="1999-05-01">Registration</change><change when="1999-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/96D855F1FBF0045844CED703B6EAF55077826366/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>John Wiley & Sons, Inc.</publisherName><publisherLoc>New York</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="50"><doi origin="wiley" registered="yes">10.1002/1531-8257(199909)14:5<>1.0.CO;2-4</doi><numberingGroup><numbering type="journalVolume" number="14">14</numbering><numbering type="journalIssue">5</numbering></numberingGroup><coverDate startDate="1999-09">September 1999</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="8" status="forIssue"><doi origin="wiley" registered="yes">10.1002/1531-8257(199909)14:5<764::AID-MDS1008>3.0.CO;2-W</doi><idGroup><id type="unit" value="MDS1008"></id></idGroup><countGroup><count type="pageTotal" number="8"></count></countGroup><titleGroup><title type="articleCategory">Article</title><title type="tocHeading1">Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 1999 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="1998-05-10"></event><event type="manuscriptRevised" date="1998-11-16"></event><event type="manuscriptAccepted" date="1999-05-01"></event><event type="firstOnline" date="2001-01-16"></event><event type="publishedOnlineFinalForm" date="2001-01-16"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:HeaderRef result:HeaderRef" date="2010-03-04"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-01"></event></eventGroup><numberingGroup><numbering type="pageFirst">764</numbering><numbering type="pageLast">771</numbering></numberingGroup><correspondenceTo>Department of Neurosciences, University “La Sapienza,” Viale dell'Università, 30‐00185‐Rome, Italy</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS1008.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="3"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="41"></count><count type="wordTotal" number="4208"></count></countGroup><titleGroup><title type="main" xml:lang="en">Increased expression of dopamine receptors on lymphocytes in Parkinson's disease</title><title type="short" xml:lang="en">Dopamine Receptors on Lymphocytes in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Piero</givenNames><familyName>Barbanti</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Giovanni</givenNames><familyName>Fabbrini</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Alberto</givenNames><familyName>Ricci</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Rosanna</givenNames><familyName>Cerbo</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Elena</givenNames><familyName>Bronzetti</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Brunella</givenNames><familyName>Caronti</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Caterina</givenNames><familyName>Calderaro</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Laura</givenNames><familyName>Felici</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Fabrizio</givenNames><familyName>Stocchi</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au10" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Giuseppe</givenNames><familyName>Meco</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au11" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Francesco</givenNames><familyName>Amenta</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au12" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Gian Luigi</givenNames><familyName>Lenzi</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="IT" type="organization"><unparsedAffiliation>Department of Neurosciences, University “La Sapienza,” Rome</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="IT" type="organization"><unparsedAffiliation>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="IT" type="organization"><unparsedAffiliation>I.R.C.C.S. Neuromed, Pozzilli and the Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, Italy</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="IT" type="organization"><unparsedAffiliation>Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, Italy</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Dopamine receptor</keyword><keyword xml:id="kwd2">Lymphocyte</keyword><keyword xml:id="kwd3">Parkinson's disease</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Dopamine D1‐like and D2‐like receptors on peripheral blood lymphocytes (PBL) were assayed in 50 <i>de novo</i> patients with idiopathic Parkinson's disease (PD), in 36 neurologic control subjects (multiple‐system atrophy, n = 16; essential tremor, n = 10; other neurodegenerative diseases, n = 10), and in 26 healthy control subjects by radioligand binding assay techniques using [<sup>3</sup>H]SCH 23390 and [<sup>3</sup>H]7OH‐DPAT as ligands. Patients with PD revealed a higher density (Bmax) of dopamine D1‐like (p <0.001) and D2‐like (p <0.00001) receptors on PBL than either neurologic or healthy control subjects, whereas no differences in Bmax were observed among patients affected by other neurologic diseases and healthy control subjects. The affinity (Kd) of both radioligands was similar in the groups investigated. The pharmacologic profile of [<sup>3</sup>H]SCH 23390 and [<sup>3</sup>H]7OH‐DPAT binding was consistent with the labeling of dopamine D5 and D3 receptor subtypes, respectively. Twenty‐five of the 50 patients with PD were retested after 3 months of therapy with levodopa or bromocriptine. Both treatments reduced the density of D1‐like (p <0.001) and D2‐like (p <0.001) receptors on PBL to values comparable to those of control subjects. The increased density of D1‐like and D2‐like receptors on PBL in <i>de novo</i> PD patients may represent an upregulation mechanism resulting from the diffuse impairment of the dopaminergic system in PD.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Increased expression of dopamine receptors on lymphocytes in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Dopamine Receptors on Lymphocytes in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Increased expression of dopamine receptors on lymphocytes in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Piero</namePart><namePart type="family">Barbanti</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation><description>Correspondence: Department of Neurosciences, University “La Sapienza,” Viale dell'Università, 30‐00185‐Rome, Italy</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giovanni</namePart><namePart type="family">Fabbrini</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alberto</namePart><namePart type="family">Ricci</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Rosanna</namePart><namePart type="family">Cerbo</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Elena</namePart><namePart type="family">Bronzetti</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Brunella</namePart><namePart type="family">Caronti</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Caterina</namePart><namePart type="family">Calderaro</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Laura</namePart><namePart type="family">Felici</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Cardiovascular and Respiratory Sciences, University “La Sapienza,” Rome</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Fabrizio</namePart><namePart type="family">Stocchi</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>I.R.C.C.S. Neuromed, Pozzilli and the Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Giuseppe</namePart><namePart type="family">Meco</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Francesco</namePart><namePart type="family">Amenta</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Section of Human Anatomy, Department of Pharmacological Sciences and Experimental Medicine, University of Camerino, Camerino, Italy</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Gian Luigi</namePart><namePart type="family">Lenzi</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurosciences, University “La Sapienza,” Rome</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>John Wiley & Sons, Inc.</publisher><place><placeTerm type="text">New York</placeTerm></place><dateIssued encoding="w3cdtf">1999-09</dateIssued><dateCaptured encoding="w3cdtf">1998-05-10</dateCaptured><dateValid encoding="w3cdtf">1999-05-01</dateValid><copyrightDate encoding="w3cdtf">1999</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">3</extent><extent unit="tables">3</extent><extent unit="references">41</extent><extent unit="words">4208</extent></physicalDescription><abstract lang="en">Dopamine D1‐like and D2‐like receptors on peripheral blood lymphocytes (PBL) were assayed in 50 de novo patients with idiopathic Parkinson's disease (PD), in 36 neurologic control subjects (multiple‐system atrophy, n = 16; essential tremor, n = 10; other neurodegenerative diseases, n = 10), and in 26 healthy control subjects by radioligand binding assay techniques using [3H]SCH 23390 and [3H]7OH‐DPAT as ligands. Patients with PD revealed a higher density (Bmax) of dopamine D1‐like (p <0.001) and D2‐like (p <0.00001) receptors on PBL than either neurologic or healthy control subjects, whereas no differences in Bmax were observed among patients affected by other neurologic diseases and healthy control subjects. The affinity (Kd) of both radioligands was similar in the groups investigated. The pharmacologic profile of [3H]SCH 23390 and [3H]7OH‐DPAT binding was consistent with the labeling of dopamine D5 and D3 receptor subtypes, respectively. Twenty‐five of the 50 patients with PD were retested after 3 months of therapy with levodopa or bromocriptine. Both treatments reduced the density of D1‐like (p <0.001) and D2‐like (p <0.001) receptors on PBL to values comparable to those of control subjects. The increased density of D1‐like and D2‐like receptors on PBL in de novo PD patients may represent an upregulation mechanism resulting from the diffuse impairment of the dopaminergic system in PD.</abstract><subject lang="en"><genre>Keywords</genre><topic>Dopamine receptor</topic><topic>Lymphocyte</topic><topic>Parkinson's disease</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><genre type="Journal">journal</genre><subject><genre>article category</genre><topic>Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>14</number></detail><detail type="issue"><caption>no.</caption><number>5</number></detail><extent unit="pages"><start>764</start><end>771</end><total>8</total></extent></part></relatedItem><identifier type="istex">96D855F1FBF0045844CED703B6EAF55077826366</identifier><identifier type="DOI">10.1002/1531-8257(199909)14:5<764::AID-MDS1008>3.0.CO;2-W</identifier><identifier type="ArticleID">MDS1008</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 1999 Movement Disorder Society</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>John Wiley & Sons, Inc.</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002075 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 002075 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= ISTEX:96D855F1FBF0045844CED703B6EAF55077826366
|texte= Increased expression of dopamine receptors on lymphocytes in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |